Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects
about
New perspectives on the role of vitiligo in immune responses to melanomaSpecific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasisIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsCD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.VISTA Regulates the Development of Protective Antitumor Immunity.T cell avidity and tumor immunity: problems and solutionsCancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.Interferon γ limits the effectiveness of melanoma peptide vaccines.Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative.Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness Cost That Is Modified by TCR Affinity during TuberculosisEnhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing miceVaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c miceCancer treatment using peptides: current therapies and future prospectsElectroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism.BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.Discovering naturally processed antigenic determinants that confer protective T cell immunity.Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance.Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.Vaccine adjuvant uses of poly-IC and derivatives.Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.Are peptide vaccines viable in combination with other cancer immunotherapies?Vaccines targeting helper T cells for cancer immunotherapy.Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.Designing therapeutic cancer vaccines by mimicking viral infections.Peptide vaccines in cancer-old concept revisited.Cancer immunotherapy: moving forward with peptide T cell vaccines.
P2860
Q26996799-036ACF38-5928-4986-947A-9B3E9571EEFFQ27310303-B4742C4B-AA59-4EF4-8C42-C006FEDB1B44Q28072532-AF2D6508-30DB-4484-AF3F-C85482F9A839Q30278537-EC10410C-71E7-417D-BF61-5224BF9AEFEEQ31047715-5941F493-C986-4F96-A036-E2892353EA1BQ31152190-8255FC8C-2DC0-4285-9D98-8D569A91F498Q33390586-E8EFECDC-5156-4F6D-831E-BD32799ADA03Q33606546-3E5B27FC-6D8A-4416-9F27-965754F8770AQ33978040-E6317D3A-270F-4E73-A5C4-624B26D2C7DAQ34115960-745E5B0D-E0AF-42C8-95C9-C8EA956C7217Q34494018-F7BC060E-D230-4BF0-B172-2A90546A81FBQ34557185-D716AD7B-B27E-4998-B5DB-B6488ADA05F7Q34568835-4FEBAF7E-BA75-4B7B-9FE5-97BF677ACDF2Q35013272-7F62C3F6-B99A-455D-BFEE-7411FE21445EQ35032671-286B697B-F6A7-4BB7-844C-CA62DDE740ABQ35152524-213EE29C-32FB-4A8A-B4EE-FEAED48BDF00Q35329190-61D99818-558A-40D4-B05D-01367C1A9F79Q35888761-BB87FDFA-5B1D-4876-A951-CCFD8C5FC2D1Q36177023-C6069A27-3A41-4E5D-B9EE-17DF7F530E86Q36245106-70F984BA-A012-498E-81C0-18608DDFD922Q36288074-F359DD18-2775-48E9-BE0F-7729B00EBE35Q36397412-3BB541EA-D587-4653-BBB4-CD2500702D80Q36515785-E246F4BF-B673-43C8-9162-B7F1FB272527Q36694876-AA5FC559-7924-475F-A1C3-60476D1E9B0BQ36763266-555CCE47-C571-407C-8FB1-505CAA7E3627Q36793499-9CACFCFA-020E-4AB5-AFAF-313F88261AADQ36891038-8F9B8E20-9201-4860-A623-C3087EA3E72AQ37389360-A4D6F264-67FC-4C2C-9A9F-9784A0938602Q37494158-73725781-DEFD-4895-9E5E-9B8D1A2036D1Q37536440-BB30AFEB-E500-4EDE-B825-098AD38F3A94Q37641401-A6E8674F-8A0C-4556-9DD0-F92B87DE4D4DQ37659577-16BA018A-9C36-4316-8714-755AF57E360CQ38259510-67538648-A8C4-41D8-BE62-9AA68CFB9C5BQ38362636-A2BE9508-41B8-4CED-A692-62B2637F0BE2Q38646990-ABAFB023-509A-421E-A9EB-DC4230E1BA8AQ38649958-0037CB87-114C-4C6D-AFDF-B2EEE93B7BD6Q38786054-FC7A66C6-8A47-4CAD-B981-D3ECE8F9D99FQ38800011-38B6CE86-3BC1-4D6E-8B8C-9E89D1A3D9CDQ39035351-386E3AAF-0AA3-4BB4-B8E0-924C3AF6BAB1Q39451757-25D69B82-1C50-40AD-B1CD-1FE3E14ED859
P2860
Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Optimized peptide vaccines eli ...... therapeutic antitumor effects
@en
Optimized peptide vaccines eli ...... therapeutic antitumor effects.
@nl
type
label
Optimized peptide vaccines eli ...... therapeutic antitumor effects
@en
Optimized peptide vaccines eli ...... therapeutic antitumor effects.
@nl
prefLabel
Optimized peptide vaccines eli ...... therapeutic antitumor effects
@en
Optimized peptide vaccines eli ...... therapeutic antitumor effects.
@nl
P2860
P1433
P1476
Optimized peptide vaccines eli ...... therapeutic antitumor effects
@en
P2093
Esteban Celis
Hyun-Il Cho
P2860
P304
P356
10.1158/0008-5472.CAN-09-2019
P407
P577
2009-11-10T00:00:00Z